Prostate tissue response after treatment with Nintedanibe in transgenic mice for adenocarcinoma (TRAMP) at different stages of tumor development

Abstract

Prostate cancer has been widely studied due to the large number of individuals affected by this type of injury, in addition to the complexity of the operation and development of this organ considering the important epithelial-stromal interaction as a primary factor for prostate alteration. Special attention has been paid to the study of inhibitors of the FGF and VEGF, as Nintedanib (BIBF 1120), a compound capable to inhibit angiogenesis, prevent cell proliferation and decrease tumor volume, used in the prevention, intervention and regression prostate cancer. Since there is no either direct cure by chemical agents for prostate cancer at an advanced stage or effective therapeutic strategies for treatment, it is necessary to priorize new studies with animals models that mimic the disease in man to know effective strategies for prevention and progression of the cancer. In the present study, the transgenic adenocarcinoma of mouse prostate (TRAMP) will be treated with Nintedanibe in 10mg/kg/dia at different stages of tumor development, ie, prostatic malignancy in early stages (8 weeks), intermediate (12 weeks) and advanced (22 weeks). After the end of treatment, the prostate ventral lobe will be collected for analysis of the structural profile, immunohistochemical and Western blotting for protein quantification and toxicity of the drug, analyzing the liver morphology. Furthermore, we will analyze the possible metastatic process and possivle adverse effects of Nintedanib in the testis of treated animals by analysis of sperm quality and quantity and immunohistochemistry. (AU)